<DOC>
	<DOC>NCT01712763</DOC>
	<brief_summary>The long acting GnRH antagonist degarelix will be tested for the treatment of women with endometriosis recurrence compared with classical GnRH analog treatment. Pain symptom disappearance and disease free time during follow-up will be the outcomes for establishing which medical treatment is the best in endometriosis recurrence treatment.</brief_summary>
	<brief_title>Degarelix in the Treatment of Endometriosis Recurrence</brief_title>
	<detailed_description>Endometriosis is a chronic disease affecting 5-10% of women in reproductive age, showing recurrence after surgery at least in 20-50% after 5 years of follow-up. The long acting GnRH antagonist degarelix, which do not have the flare-up effect at the opposite of GnRH agonist and strongly suppress LH secretion and thecal cell activity may show a better effects on endometrial implants than GnRH agonist.</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<criteria>women affected by endometriosis showing recurrence of pain symptoms previous surgery for endometriosis presence of other systemic diseases</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Endometriosis</keyword>
	<keyword>long acting GnRH antagonist</keyword>
	<keyword>Degarelix</keyword>
	<keyword>Recurrence</keyword>
	<keyword>Pelvic Pain</keyword>
</DOC>